Ultimately, both the changes in SIINFEKL-loaded H2-Kb and IFN-γ production by OT1 cells indicated that Hsp90 inhibition in cancer cells can result in higher activation of tumour-specific CD8+ T cells. The gene discussed is CD8A; the disease is cancer.